Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb …

Among subjects with EoE, there were no reports of conjunctivitis and keratitis in the DUPIXENT group in placebo-controlled trials. In the 36-week active treatment extension period of Study …

Sep 11, 2025 · A meta-analysis of five retrospective studies encompassing 209 subjects with EoE treated with Dupixent showed that around 90% of patients experienced symptom …

Jun 27, 2024 · Dupilumab resulted in histologic remission in a significantly higher percentage of children with eosinophilic esophagitis than placebo. The higher-exposure dupilumab regimen …

Dec 21, 2022 · Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. We conducted a …

Jan 25, 2024 · 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these …

The Disease Eosinophilic esophagitis (EoE) is a long-term, inflammatory disease of the esophagus, affecting children and adults In children, it causes symptoms such as vomiting, …

Feb 21, 2024 · The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed the …

May 22, 2020 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent ® (dupilumab) in …

Jan 25, 2024 · Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) January 25, 2024 14:29 …